Install
Research shows gut microbiome could delay onset of type 1 diabetes Race opens first Australian clinical site for RC220 Phase 1 solid tumour trial Biome secures news debt facility to support growth Algorae announces the appointment of chief commercial officer Percheron updates shareholders after disappointing clinical t
- 27articles · 30d
- 8+ hour agolatest article
- Aug 17, 2026earliest in window
- 96%with images
- 343avg words
- Medical 21
- Health & Wellness 18
- Health 11
- Economy, Business & Finance 10
- Business & Industrial 5
- Science & Technology 5
- Finance & Business 4
- News 4
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Noxopharm moves lupus skin therapy toward next human trial
8+ hour, 41+ min ago (292+ words) Noxopharm has announced that its lead experimental therapy, SOF-SKN, will advance to an extension clinical study in patients with cutaneous lupus erythematosus, a painful and disfiguring skin condition for which no targeted treatment currently exists. The Sydney-based company said the…...
Radiopharm imaging trial offers new hope for pancreatic cancer detection
5+ day, 6+ hour ago (245+ words) Radiopharm Theranostics has reported encouraging early results from a Phase 1 imaging trial of its experimental agent RAD301 in patients with pancreatic ductal adenocarcinoma, one of the most lethal and hardest to treat forms of cancer. The Sydney-based, dual-listed biopharmaceutical company, which…...
OncoSil marks a milestone moment for pancreatic cancer patients in Spain
5+ day, 9+ hour ago (239+ words) A hospital in Madrid has reached a notable milestone for OncoSil Medical, with the Australian medical device company confirming that its device has now been used to treat its 100th patient in Spain. The procedure took place at Hospital HM Sanchinarro....
Arovella Therapeutics moves 'off-the-shelf' cell therapy from lab to patients
1+ week, 11+ hour ago (412+ words) BiotechDispatch Arovella Therapeutics moves 'off-the-shelf' cell therapy from lab to patients Arovella Therapeutics has taken a step toward treating blood cancer patients with donor-derived cells rather than their own, announcing that it has released its first clinical manufacturing batch of…...
Prescient reaches key PTX-100 trial checkpoint ahead of December review
1+ week, 4+ day ago (338+ words) Prescient Therapeutics has reached an enrolment milestone in its Phase 2a trial of PTX-100 for patients with relapsed or refractory cutaneous T-cell lymphoma, setting the company up for a planned dose optimisation review in December. The Melbourne-based clinical-stage oncology company said…...
Telix completes BiPASS enrolment as it pursues a broader role for PSMA PET
1+ week, 4+ day ago (396+ words) Telix Pharmaceuticals has completed enrolment in its pivotal BiPASS trial, moving the Australian company closer to testing whether its gallium-based PSMA PET imaging agents can help determine which men with suspected prostate cancer need a biopsy in the first place....
Cartherics pursues new cell therapy route for cancer and endometriosis
1+ week, 6+ day ago (421+ words) Melbourne company Cartherics is joining forces with the Zucker Institute at the Medical University of South Carolina to investigate whether a novel antibody can strengthen next-generation immune cell therapies for solid tumours and endometriosis. The collaboration will combine Cartherics’ induced…...
Professor Fiona Wood to give Depaz Oration at AusBiotech International Conference
3+ week, 4+ day ago (252+ words) World-renowned plastic and reconstructive surgeon, Professor Fiona Wood AO, has been announced as the Depaz Orator for the AusBiotech International Conference, held as part of Australia’s Biggest Week in Biotech on the Gold Coast in October 2026. Professor Wood is a…...
Mesoblast completes treatment in pivotal low back pain trial as phase 3 readout approaches
3+ week, 6+ day ago (340+ words) Mesoblast has completed treatment of all 350 patients in its pivotal phase 3 trial of rexlemestrocel-L for chronic low back pain caused by inflammatory degenerative disc disease, putting the company on track for top-line results in mid-2027. The trial, known as MSB-DR004, is…...